




TITLE: How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion

Principal investigator: Prof. Fausto Salaffi, fausto.salaffi@gmail.com, tel: 0731 534128

UNIVPM Research Group: DISCLIMO, Clinica Reumatologica

Research activity description: At the time of writing, Italy has the third highest number of COVID-19 cases after USA and Spain; consequently, its experience may be useful for other countries that have not yet had to face the full force of the disease. Lombardy is the Italian region with the highest number of recorded cases (34.507 as of April 1, or 47.3% of the total); the corresponding figures in the neighbouring regions of Emilia-Romagna and Veneto are respectively 10,008 (13.6%) and 6,935 (9.4%). To the best of our knowledge, there are still no studies that have considered how to handle IBD and rheumatic patients with COVID-19. Given the experience of Milan's Luigi Sacco University Hospital (a reference centre for infectious emergencies in Lombardy and Marche, we believe that it is worth sharing the strategic therapeutic plan for autoimmune patients treated with conventional treatments





UNIVERSITÀ
POLITECNICA
DELLE MARCHE

**RESEARCH AREA:
EPIDEMIOLOGY**

and immunosuppressive/modulatory drugs developed by our gastroenterology, rheumatology and infectious disease units.

Link: <https://www.sciencedirect.com/science/article/pii/S1568997220301361>

Collaborators: ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan.
